COVID-19 Treatment Developed In St. Louis To Begin Human Trials
St. Louis on the Air · St. Louis Public Radio
June 23, 202014m 18s
Audio is streamed directly from the publisher (kwmu-adswizz.streamguys1.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A drug developed in St. Louis is beginning human trials with the idea of helping those most at risk of dying from COVID-19. ATI-450 was originally developed by Confluence Discovery Technologies in 2013 as a treatment for autoimmune diseases, particularly rheumatoid arthritis. Confluence co-founder Joe Monahan discusses with host Sarah Fenske how it might now also help with the new coronavirus -- and what it will take to bring it to market.